Julie Khlevner, MD, AGAF, explains the impact of the FDA approval of linaclotide for pediatric IBS-C - Contemporary Pediatrics

Julie Khlevner, MD, AGAF, explains the impact of the FDA approval of linaclotide for pediatric IBS-C  Contemporary Pediatrics

Pediatric gastroenterologists now have a newly approved treatment option for children and adolescents with irritable bowel syndrome with constipation (IBS-C) following the FDA’s recent approval of linaclotide (Linzess) capsules for patients ≥7 years of age. This approval marks the first pharmacologic therapy for IBS-C in this population, expanding on linaclotide’s prior approvals for chronic idiopathic constipation and functional constipation in children.

Julie Khlevner, MD, AGAF, associate professor of Pediatrics at Columbia University Medical Center; chair, NASPGHAN Neurogastroenterology and Motility Committee, discussed news of the approval at the 2025 North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), describing the approval as “Exciting! We have been looking for treatment options for these patients for a really long time, so it’s nice to have an FDA approval in the pharmacological space at this time."

View the full article